Improving Outcomes for Women with Type 2 Diabetes
Individualizing Evidence-Based Care
Meeting Slides
Guidelines
American Diabetes Association—Standards of Medical Care in Diabetes—2015
American Diabetes Association. Diabetes Care. 2015;38(suppl 1):S1-S93.
American Diabetes Association—Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association. Diabetes Care. 2014;37(suppl 1):S81-S90.
National Standards for Diabetes Self-Management Education and Support
Haas L, et al. Diabetes Care. 2014;37(suppl 1):S144-S153.
American Association of Clinical Endocrinologists and American College of Endocrinology—Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan—2015
Handelsman Y, et al. Endocr Pract. 2015;21(suppl 1):1-87.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach—Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Inzucchi SE, et al. Diabetes Care. 2015;38(1):140-149.
Suggested Readings
Sex Differences in Type 2 Diabetes: Focus on Disease Course and Outcomes
Arnetz L, et al. Diabetes Metab Syndr and Obes. 2014;7:409-420.
Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women
Baldani DP, et al. Int J of Endocrinol. 2015;2015:786362.
Parity and Diabetes Risk Among Hispanic Women From Colombia: Cross-sectional Evidence
Cure P, et al. Diabetol Metab Syndr. 2015;7:7.
Women Are Diagnosed With Type 2 Diabetes at Higher Body Mass Indices and Older Ages than Men: Korea National Health and Nutrition Examination Survey 2007-2010
Kwon SK. Diabetes Metab J. 2014;38(1):74-80 .
Impact of Sex on the Heart’s Metabolic and Functional Responses to Diabetic Therapies
Lyons MR, et al. Am J Physiol Heart Circ Physiol. 2013;305(11):H1584-H1591.
Diabetes Abrogates Sex Differences and Aggravates Cardiometabolic Risk in Postmenopausal Women
Mascarenhas-Melo F, et al. Cardiovasc Diabetol. 2013;12:61.
Sex Differences in the Excess Risk of Cardiovascular Diseases Associated With Type 2 Diabetes: Potential Explanations and Clinical Implications
Peters SAE, et al. Curr Cardiovasc Risk Rep. 2015;9(7):36.
Sex Differences in the Metabolic Syndrome: Implications for Cardiovascular Health in Women
Pradhan AD. Clin Chem. 2014;60(1):44-52.
Factors Associated With a Diabetes Diagnosis and Late Diabetes Diagnosis for Males and Females
Roche MM, Wang PP. J of Clin Transl Endocrinol. 2014;1(3):77-84.
Sex Differences in All-Cause and Cardiovascular Mortality, Hospitalization for Individuals With and Without Diabetes, and Patients With Diabetes Diagnosed Early and Late
Roche MM, Wang PP. Diabetes Care. 2013;36(9):2582-2590.
Educational Materials for Patients, Family Members, and Caregivers
American Diabetes Association—Women
WomensHealth.gov—The Healthy Woman: A Complete Guide for All Ages—Type 2 Diabetes
CDC.gov—Diabetes in Women
Interactive PresentationPractice Pearls for Improving Outcomes for Women with T2DM
Eileen Egan, DNP, FNP-C, CDE
Individualizing Evidence-Based Care
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Looking Beyond Hemoglobin A1c
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Implications for PCSK9 Inhibitors in Clinical Practice
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Multidimensional Outcomes With SGLT2 Inhibitors
New Avenues to Improve Patient Outcomes
